Results: 13
Manganese improves anti-PD-L1 immunotherapy via eliciting type I interferon signaling in melanoma.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 6, p. 685, doi. 10.1007/s10637-024-01484-6
- By:
- Publication type:
- Article
Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 6, p. 703, doi. 10.1007/s10637-024-01483-7
- By:
- Publication type:
- Article
Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 6, p. 675, doi. 10.1007/s10637-024-01482-8
- By:
- Publication type:
- Article
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 6, p. 664, doi. 10.1007/s10637-024-01481-9
- By:
- Publication type:
- Article
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 6, p. 655, doi. 10.1007/s10637-024-01480-w
- By:
- Publication type:
- Article
Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 6, p. 644, doi. 10.1007/s10637-024-01479-3
- By:
- Publication type:
- Article
Unraveling the potential biomarkers of immune checkpoint inhibitors in advanced ovarian cancer: a comprehensive review.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 6, p. 728, doi. 10.1007/s10637-024-01478-4
- By:
- Publication type:
- Article
Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 6, p. 623, doi. 10.1007/s10637-024-01477-5
- By:
- Publication type:
- Article
Clinical research progress of fruquintinib in the treatment of malignant tumors.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 6, p. 612, doi. 10.1007/s10637-024-01476-6
- By:
- Publication type:
- Article
Gremlin1: a BMP antagonist with therapeutic potential in Oncology.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 6, p. 716, doi. 10.1007/s10637-024-01474-8
- By:
- Publication type:
- Article
Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 6, p. 603, doi. 10.1007/s10637-024-01473-9
- By:
- Publication type:
- Article
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 6, p. 635, doi. 10.1007/s10637-024-01471-x
- By:
- Publication type:
- Article
Neoadjuvant immunochemotherapy in locally advanced laryngeal cancer and hypopharyngeal cancer: higher objective response rate and organ-preservation rate.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 6, p. 694, doi. 10.1007/s10637-024-01456-w
- By:
- Publication type:
- Article